Development
Biodesix, Inc.
BDSX
$0.3029
$0.02117.49%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 49.09M | 44.03M | 41.64M | 40.72M | 38.21M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 49.09M | 44.03M | 41.64M | 40.72M | 38.21M |
| Cost of Revenue | 13.01M | 12.94M | 13.35M | 14.09M | 14.15M |
| Gross Profit | 36.08M | 31.08M | 28.30M | 26.63M | 24.06M |
| SG&A Expenses | 67.39M | 67.76M | 67.38M | 65.96M | 61.46M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 90.39M | 92.37M | 93.42M | 93.20M | 88.72M |
| Operating Income | -41.30M | -48.34M | -51.78M | -52.48M | -50.51M |
| Income Before Tax | -52.15M | -63.35M | -66.10M | -68.56M | -65.45M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -52.15 | -63.35 | -66.10 | -68.56 | -65.45 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.15M | -63.35M | -66.10M | -68.56M | -65.45M |
| EBIT | -41.30M | -48.34M | -51.78M | -52.48M | -50.51M |
| EBITDA | -37.97M | -45.09M | -48.42M | -49.01M | -46.91M |
| EPS Basic | -0.65 | -0.90 | -1.10 | -1.33 | -1.60 |
| Normalized Basic EPS | -0.40 | -0.52 | -0.64 | -0.74 | -0.90 |
| EPS Diluted | -0.65 | -0.90 | -1.10 | -1.33 | -1.60 |
| Normalized Diluted EPS | -0.40 | -0.52 | -0.64 | -0.74 | -0.90 |
| Average Basic Shares Outstanding | 328.31M | 293.79M | 254.52M | 215.26M | 168.56M |
| Average Diluted Shares Outstanding | 328.31M | 293.79M | 254.52M | 215.26M | 168.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |